Target intelligence / Profile preview

Caspase recruitment domain-containing protein 9 (CARD9)

Target
CARD9
Molecular classification
Adapter protein, Scaffold protein, Other (member of the CARD-CC protein family)
01

Overview

Caspase recruitment domain-containing protein 9 (CARD9) is an adapter protein involved in innate and adaptive immunity. Highly expressed in myeloid cells, CARD9 transduces signals from pattern recognition receptors (e.g., C-type lectin receptors) to activate NF-κB and mediate pro-inflammatory and anti-inflammatory cytokine production. Homozygous mutations in CARD9 lead to a marked susceptibility to fungal infections due to impaired innate immune responses. CARD9 also plays roles in inflammation and may contribute to cancer progression, notably acting as an independent prognostic marker in lung adenocarcinoma. As a scaffold protein, CARD9 interacts with other CARD domain-containing proteins to assemble signaling complexes, modulating host defense and immune cell activation.

Other names
CARD9Caspase recruitment domain family member 9
02

Mechanism of action

Modulation of inflammatory signaling; drugs aiming at CARD9 could interfere with signal transduction pathways downstream of pattern recognition receptors, thus impacting NF-κB activation, cytokine production, and immune cell function

03

Biological functions

Innate immune responseInflammationSignal transduction for pattern recognition receptorsActivation of NF-κB signaling pathwayRegulation of cytokine production
04

Disease associations

Infection (particularly fungal infections such as Candida and dermatophytes)Cancer (including a prognostic association with lung adenocarcinoma and thyroid cancer)Immune deficiencyInflammation
05

Safety considerations

Potential immunosuppression (modulating CARD9 may impair anti-fungal immune defense and increase infection risk)Possible impact on inflammation and tumor progression
06

Interacting drugs

null (no drugs with direct, approved CARD9 modulation currently known; considered a molecular target in early-stage drug discovery and research)
07

Biomarkers

CARD9 expression level in tumors as a prognostic biomarker for lung adenocarcinomaGenetic variants/mutations in CARD9 as biomarkers for susceptibility to immunodeficiency or fungal infection

Beyond the preview

Go deeper on Caspase recruitment domain-containing protein 9 (CARD9).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Caspase recruitment domain-containing protein 9 (CARD9).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call